Role of faecal gas analysis for the diagnosis of IBD

2011 ◽  
Vol 39 (4) ◽  
pp. 1079-1080 ◽  
Author(s):  
Chris S.J. Probert
Keyword(s):  
Gastrointestinal Diseases ◽  
Gas Analysis ◽  
Non Invasive ◽  
Disease States ◽  
Faecal Samples ◽  
Volatile Organic ◽  
Headspace Gas ◽  
Inflammatory Bowel ◽  
Symptoms And Signs

The diagnosis of IBD (inflammatory bowel disease) is based on the clinical evaluation of symptoms and signs leading to a series of investigations. The investigations used are often unpleasant for patients; they are invasive, costly and potentially dangerous. Patients often report that the odour of flatus, or the gas emitted from faeces, is abnormal during a flare of their IBD. Our group has characterized the VOCs (volatile organic compounds) in the headspace gas emitted from faecal samples from healthy subjects, from patients with infectious diarrhoea and from those with Crohn's disease or ulcerative colitis, both in relapse and remission. Painstaking analysis of gas chromatography–MS data (VOC profiling) has revealed patterns of compounds that are strongly associated with specific infectious diseases and with IBD. These compounds represent a change in the microflora and/or the metabolism of bacteria and/or the epithelium in disease states. These profiles offer a potential for rapid non-invasive assessment of a range of infectious and non-infectious gastrointestinal diseases. The study of VOCs may lead to a better understanding of the pathogenesis of IBD.

scholarly journals Dietary Modulation of Bacteriophages as an Additional Player in Inflammation and Cancer

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2036
Author(s):  
Luigi Marongiu ◽  
Markus Burkard ◽  
Sascha Venturelli ◽  
Heike Allgayer
Keyword(s):  
Structural Damage ◽  
Folk Medicine ◽  
Gastrointestinal Diseases ◽  
Potential Contribution ◽  
Anticancer Properties ◽  
Specific Phage ◽  
Microbial Network ◽  
Inflammatory Bowel ◽  
Species Specific

Natural compounds such as essential oils and tea have been used successfully in naturopathy and folk medicine for hundreds of years. Current research is unveiling the molecular role of their antibacterial, anti-inflammatory, and anticancer properties. Nevertheless, the effect of these compounds on bacteriophages is still poorly understood. The application of bacteriophages against bacteria has gained a particular interest in recent years due to, e.g., the constant rise of antimicrobial resistance to antibiotics, or an increasing awareness of different types of microbiota and their potential contribution to gastrointestinal diseases, including inflammatory and malignant conditions. Thus, a better knowledge of how dietary products can affect bacteriophages and, in turn, the whole gut microbiome can help maintain healthy homeostasis, reducing the risk of developing diseases such as diverse types of gastroenteritis, inflammatory bowel disease, or even cancer. The present review summarizes the effect of dietary compounds on the physiology of bacteriophages. In a majority of works, the substance class of polyphenols showed a particular activity against bacteriophages, and the primary mechanism of action involved structural damage of the capsid, inhibiting bacteriophage activity and infectivity. Some further dietary compounds such as caffeine, salt or oregano have been shown to induce or suppress prophages, whereas others, such as the natural sweeter stevia, promoted species-specific phage responses. A better understanding of how dietary compounds could selectively, and specifically, modulate the activity of individual phages opens the possibility to reorganize the microbial network as an additional strategy to support in the combat, or in prevention, of gastrointestinal diseases, including inflammation and cancer.

scholarly journals Nitric Oxide and Biological Mediators in Pediatric Chronic Rhinosinusitis and Asthma

2019 ◽  
Vol 8 (11) ◽  
pp. 1783 ◽  
Author(s):  
Valentina Agnese Ferraro ◽  
Stefania Zanconato ◽  
Eugenio Baraldi ◽  
Silvia Carraro
Keyword(s):  
Nitric Oxide ◽  
Chronic Rhinosinusitis ◽  
Exhaled Breath Condensate ◽  
Main Body ◽  
Exhaled Breath ◽  
Non Invasive ◽  
Volatile Organic ◽  
Exhaled Air ◽  
Breath Condensate

Background: In the context of the so-called unified airway theory, chronic rhinosinusitis (CRS) and asthma may coexist. The inflammation underlying these conditions can be studied through the aid of biomarkers. Main body: We described the main biological mediators that have been studied in pediatric CRS and asthma, and, according to the available literature, we reported their potential role in the diagnosis and management of these conditions. As for CRS, we discussed the studies that investigated nasal nitric oxide (nNO), pendrin, and periostin. As for asthma, we discussed the role of fractional exhaled nitric oxide (feNO), the role of periostin, and that of biological mediators measured in exhaled breath condensate (EBC) and exhaled air (volatile organic compounds, VOCs). Conclusion: Among non-invasive biomarkers, nNO seems the most informative in CRS and feNO in asthma. Other biological mediators seem promising, but further studies are needed before they can be applied in clinical practice.

scholarly journals Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science

Cells ◽  
2019 ◽  
Vol 8 (6) ◽  
pp. 548 ◽  
Author(s):  
Dario Sorrentino ◽  
Vu Q. Nguyen ◽  
Maithili V. Chitnavis
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Clinical Stage ◽  
Major Drawback ◽  
Disease Etiology ◽  
Non Invasive ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Potential Impact ◽  
Made In

While much progress has been made in the last two decades in the treatment and the management of inflammatory bowel diseases (IBD)—both ulcerative colitis (UC) and Crohn’s Disease (CD)—as of today these conditions are still diagnosed only after they have become symptomatic. This is a major drawback since by then the inflammatory process has often already caused considerable damage and the disease might have become partially or totally unresponsive to medical therapy. Late diagnosis in IBD is due to the lack of accurate, non-invasive indicators that would allow disease identification during the pre-clinical stage—as it is often done in many other medical conditions. Here, we will discuss what is known about the biologic onset and pre-clinical CD with an emphasis on studies conducted in patients’ first degree relatives. We will then review the possible strategies to diagnose IBD very early in time including screening, available disease markers and imaging, and the possible clinical implications of treating these conditions at or close to their biologic onset. Later, we will review the potential impact of conducting translational research in IBD during the pre-clinical stage, especially focusing on the role of the microbiome in disease etiology and pathogenesis. Finally, we will highlight possible future developments in the field and how they can impact IBD management and our scientific knowledge of these conditions.

Vedolizumab

2016 ◽  
Vol 29 (5) ◽  
pp. 503-515 ◽  
Author(s):  
Mara Poulakos ◽  
Jade D. Machin ◽  
Julienne Pauly ◽  
Yasmin Grace
Keyword(s):  
Intestinal Barrier ◽  
Relevant Information ◽  
Intestinal Barrier Function ◽  
Disease States ◽  
Bowel Diseases ◽  
Biologic Response ◽  
Patients At Risk ◽  
Inflammatory Bowel ◽  
The Brain

Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders affecting the gastrointestinal (GI) tract that encompass Crohn’s disease (CD) and ulcerative colitis (UC). In these disease states, epithelial damage of the intestinal mucosa is evident due to increased lymphocyte trafficking to the area, which affects the normal intestinal barrier function. Currently available pharmacotherapy can be limited in terms of efficacy and associated toxicities. Newer agents have emerged, including the monoclonal antibody natalizumab, which antagonizes integrin, an important component within the inflammation cascade. Natalizumab works by modulating both the GI and brain biologic responses and as a result there is risk of the opportunistic infection known as progressive multifocal leukoencephalopathy (PML), putting patients at risk for severe disability and death. Vedolizumab, another integrin inhibitor, is selective for modulating the gut biologic response but not the brain, consequently decreasing the risk for PML. To generate information regarding the role of vedolizumab in the treatment of IBD, a literature search was conducted, yielding 7 phase I to III clinical trials. This article serves as a summary of efficacy, safety, and other relevant information from clinical studies to explore the role of vedolizumab in the treatment of CD and UC.

scholarly journals Antimicrobial Peptides in Gastrointestinal Inflammation

2010 ◽  
Vol 2010 ◽  
pp. 1-11 ◽  
Author(s):  
Simon Jäger ◽  
Eduard F. Stange ◽  
Jan Wehkamp
Keyword(s):  
Antimicrobial Peptides ◽  
Intestinal Inflammation ◽  
Disease States ◽  
Mucosal Surfaces ◽  
Bowel Diseases ◽  
Inflammatory Processes ◽  
Complex Events ◽  
Inflammatory Bowel ◽  
Adaptive Immune Systems

Acute and chronic inflammations of mucosal surfaces are complex events in which the effector mechanisms of innate and adaptive immune systems interact with pathogenic and commensal bacteria. The role of constitutive and inducible antimicrobial peptides in intestinal inflammation has been investigated thoroughly over the recent years, and their involvement in various disease states is expanded ever more. Especially in the intestines, a critical balance between luminal bacteria and the antimicrobial peptides is essential, and a breakdown in barrier function by impaired production of defensins is already implicated in Crohn's disease. In this paper, we focus on the role of antimicrobial peptides in inflammatory processes along the gastrointestinal tract, while considering the resident and pathogenic flora encountered at the specific sites. The role of antimicrobial peptides in the primary events of inflammatory bowel diseases receives special attention.

scholarly journals Tryptophan Metabolites Along the Microbiota-Gut-Brain Axis: An Interkingdom Communication System Influencing the Gut in Health and Disease

2020 ◽  
Vol 13 ◽  
pp. 117864692092898 ◽  
Author(s):  
Annalisa Bosi ◽  
Davide Banfi ◽  
Michela Bistoletti ◽  
Cristina Giaroni ◽  
Andreina Baj
Keyword(s):  
Communication System ◽  
Gastrointestinal Diseases ◽  
Disease States ◽  
Bidirectional Communication ◽  
Tryptophan Metabolites ◽  
Health And Disease ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
Preclinical And Clinical Studies ◽  
Interkingdom Communication

The ‘microbiota-gut-brain axis’ plays a fundamental role in maintaining host homeostasis, and different immune, hormonal, and neuronal signals participate to this interkingdom communication system between eukaryota and prokaryota. The essential aminoacid tryptophan, as a precursor of several molecules acting at the interface between the host and the microbiota, is fundamental in the modulation of this bidirectional communication axis. In the gut, tryptophan undergoes 3 major metabolic pathways, the 5-HT, kynurenine, and AhR ligand pathways, which may be directly or indirectly controlled by the saprophytic flora. The importance of tryptophan metabolites in the modulation of the gastrointestinal tract is suggested by several preclinical and clinical studies; however, a thorough revision of the available literature has not been accomplished yet. Thus, this review attempts to cover the major aspects on the role of tryptophan metabolites in host-microbiota cross-talk underlaying regulation of gut functions in health conditions and during disease states, with particular attention to 2 major gastrointestinal diseases, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), both characterized by psychiatric disorders. Research in this area opens the possibility to target tryptophan metabolism to ameliorate the knowledge on the pathogenesis of both diseases, as well as to discover new therapeutic strategies based either on conventional pharmacological approaches or on the use of pre- and probiotics to manipulate the microbial flora.

scholarly journals Exploring the role of the microbiota member Bifidobacterium in modulating immune-linked diseases

2017 ◽  
Vol 1 (4) ◽  
pp. 333-349 ◽  
Author(s):  
Ian O'Neill ◽  
Zoe Schofield ◽  
Lindsay J. Hall
Keyword(s):  
Critical Period ◽  
Immune Modulation ◽  
Future Directions ◽  
Immune Development ◽  
Disease States ◽  
Physiological Processes ◽  
Inflammatory Bowel ◽  
Different Strains ◽  
Immune Maturation

The gut-associated microbiota is essential for multiple physiological processes, including immune development. Acquisition of our initial pioneer microbial communities, including the dominant early life genus Bifidobacterium, occurs at a critical period of immune maturation and programming. Bifidobacteria are resident microbiota members throughout our lifetime and have been shown to modulate specific immune cells and pathways. Notably, reductions in this genus have been associated with several diseases, including inflammatory bowel disease. In this review, we provide an overview of bifidobacteria profiles throughout life and how different strains of bifidobacteria have been implicated in immune modulation in disease states. The focus will be examining preclinical models and outcomes from clinical trials on immune-linked chronic conditions. Finally, we highlight some of the important unresolved questions in relation to Bifidobacterium-mediated immune modulation and implications for future directions, trials, and development of new therapies.

189 Analysis of Volatile Organic Compounds in Exhaled Air As a Non Invasive Biomarker for Inflammatory Bowel Disease (IBD)

2009 ◽  
Vol 136 (5) ◽  
pp. A-35 ◽  
Author(s):  
Alexander Bodelier ◽  
Marie J. Pierik ◽  
Jan W. Dallinga ◽  
Joep Van Berkel ◽  
Edwin Moonen ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Volatile Organic Compounds ◽  
Organic Compounds ◽  
Bowel Disease ◽  
Non Invasive ◽  
Volatile Organic ◽  
Exhaled Air ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document